ADC Therapeutics SA filed an 8-K on November 4, 2026, announcing that new and updated clinical data from the ZYNLONTA (loncastuximab tesirine-lpyl) program will be presented across five oral sessions and multiple posters at the 68th American Society of Hematology Annual Meeting, December 12-15, 2026, in New Orleans, Louisiana.

Key Highlights

  • LOTIS-7 ORR: Among 97 efficacy-evaluable r/r DLBCL patients, the overall response rate was 88.7% and the complete response rate was 75.3% with ZYNLONTA plus glofitamab, as of the June 15, 2026 data cutoff.
  • Durable responses: At a median follow-up of 10.35 months, median duration of response, duration of complete response, and progression-free survival had not been reached; the 12-month duration of complete response rate was 79.0%.
  • MZL Phase 2 IIT: Among 43 efficacy-evaluable patients with relapsed or refractory marginal zone lymphoma, ORR was 93% and CRR was 74.4%, with a two-year PFS rate of 90.8% at a median follow-up of 23.2 months.
  • LOTIS-5 Phase 3 primary endpoint met: Median PFS was 6.14 months with ZYNLONTA plus rituximab versus 4.73 months with R-GemOx (HR 0.73; 95% CI, 0.57-0.92; P=0.0083) in 420 patients.
  • Five oral presentations: ZYNLONTA data will be featured in five oral sessions at ASH 2026, covering r/r DLBCL, marginal zone lymphoma, mantle cell lymphoma, and Waldenstrom macroglobulinemia.
  • LOTIS-5 safety window: Within the protocol-defined 105-day reporting window, Grade 5 treatment-emergent adverse events occurred in 13.2% of the ZYNLONTA-plus-rituximab arm versus 4.6% with R-GemOx; using a standard 30-day post-treatment window, Grade 5 events occurred in 1.5% versus 3.0%, respectively.

ZYNLONTA Clinical Program Data Ahead of ASH 2026

According to the filing, ADC Therapeutics (NYSE:ADCT) disclosed updated results from LOTIS-7, a Phase 1b study evaluating ZYNLONTA in combination with glofitamab in patients with relapsed or refractory large B-cell lymphoma. At the ZYNLONTA 150 µg/kg starting dose plus glofitamab, and as of the June 15, 2026 data cutoff, 52.4% of patients were primary refractory and had received a median of one prior treatment (range 1-5). In patients with primary refractory disease, the ORR was 78.4% and the CRR was 64.7%. Among patients previously treated with prior CAR-T therapy, the ORR was 74.1% and the CRR was 63.0%. The filing noted that cytokine release syndrome occurred in 32% of treated patients, predominantly Grade 1 (25.2%) or Grade 2 (5.8%), with one Grade 3 CRS event and no Grade 3 or higher ICANS events; three Grade 5 treatment-emergent adverse events were reported.

The filing also disclosed results from a multicenter Phase 2 investigator-initiated trial of fixed-duration ZYNLONTA in relapsed or refractory marginal zone lymphoma. As of the July 1, 2026 data cutoff, among 43 efficacy-evaluable patients, ORR was 93% and CRR was 74.4%, with 37% having primary refractory disease and 42% having experienced disease progression within 24 months of initial therapy. The filing stated that the duration of response rate at 24 months was 90.9%. Grade 3 adverse events (36 events) were reported in 23 patients (50%), and Grade 4 adverse events (5 events) in five patients (10.9%). Four patients required dose reductions.

Regarding the Phase 3 LOTIS-5 study, the filing reported full results from 420 randomized patients. No statistically significant difference in overall survival was observed between treatment arms, according to the filing. The authors, as characterized in the filing, conclude that "ZYNLONTA plus rituximab as a standard treatment option in the second-line or later setting." The company also stated that forward-looking statements in the release are subject to its cautionary language regarding risks and uncertainties.

What Was Disclosed

ADC Therapeutics disclosed updated efficacy and safety data from multiple ZYNLONTA clinical studies to be presented at ASH 2026, including Phase 1b, Phase 2, and Phase 3 results across several B-cell lymphoma indications, with five oral presentations scheduled between December 12 and 14, 2026.